Anti-Metastatic Study of Liposome-Encapsulated AlltransRetinoic Acid (ATRA) in B16F10 Melanoma Cells-Implanted C57BL/6 Mice

Abstract

B16F10 cells-induced C57BL/6 mice were divided into several groups and the free all trans retinoic acid (ATRA) and liposome-encapsulated ATRA were given for 21 days. The encapsulated ATRA treatment lowered the oxidative stress and lipid profile near to the normal level in the drug-treated mice. Encapsulated ATRA treatment showed substantial decrease in serum cytokines and increase in lifespan when compared with free ATRA treatment. These results imply that the liposome-encapsulated ATRA may help to achieve a higher level of ATRA in comparison with free ATRA treatment and helps to enhance anticancer drug delivery in liposome-encapsulated ATRA treatment.

Topical treatment of all‐trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T‐cell immunity

“…b), which excluded the possibility that NK cells mediate the therapeutic effect of atRA on established B16F10 tumour. AtRA can induce apoptosis of many types of cancer cells including melanoma at high non‐physiological concentrations . Consistently, we found that atRA at higher concentration (10 μ m ) could significantly induce the apoptosis of B16F10 cells, suggesting that the direct pro‐apoptotic effect of atRA on melanoma cells may also contribute to the inhibition of B16F10 tumour growth in vivo .…”

“…A recent study showed that taking vitamin A supplements may be able to decrease the risk of developing melanoma, suggesting a beneficial effect of atRA in melanoma. Most previous studies focused on the direct inhibitory effect of atRA on the biology of melanoma cells in vitro . There are only two studies focusing on the immunoregulatory role of atRA in melanoma, showing the opposing effect.…”

“…Most previous studies focused on the direct inhibitory effect of atRA on the biology of melanoma cells in vitro. [24][25][26] There are only two studies focusing on the immunoregulatory role of atRA in melanoma, showing the opposing effect. Guo et al 27 demonstrated that genetic interruption of RARa, the primary functional receptor of atRA, in CD8 + T cells aggravated B16F10 tumour growth in CD4-depleted mice.…”

Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes

“…46 Retinoids have been used as chemotherapeutics and in the adjuvant setting in a variety of cancers; however, ATRA is less effective in treating solid tumors, which may be due to its reduced aqueous solubility limiting sufficient quantities delivered to the tumor sites. 47 Reports on the effectiveness of ATRA therapy in melanoma have also been conflicting. ATRA has been shown to inhibit growth of normal human melanocytes, while its effectiveness in melanoma cell lines was shown to be minimal.…”

“…One recent study tested a formulation of a liposome encapsulated ATRA in comparison to free ATRA in a mouse model of lung metastasis using tail vein-injected mouse melanoma cell line B16F10. 47 Compared to free ATRA, the authors observed that encapsulated ATRA achieved an increased lifespan, and reduced lung tumor nodules and tumor markers at a low dose (0.60 mg/kg per day), while also reducing several unwanted side effects of ATRA therapy, including reducing oxidative stress, lipid profiles, increasing T-helper type 1 (Th1) cytokines, and decreasing Th2 cytokines. Given these findings, the results of this study also warrant further testing of tretinoin in melanoma at lower doses through other delivery systems to reduced unwanted side effects.…”